ArticleOncology letters2018
Expression of AQP3 and AQP5 as a prognostic marker in triple-negative breast cancer.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.Nature medicine · 2023Trial
- Review
- Aquaporin 5 and Nuclear Factor Erythroid 2-Related Factor 2 Upregulation in Tumor and Stroma Is Associated with Poor Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026Article
- Aquaporin-3 and aquaporin-5 impact the development of pancreatic ductal adenocarcinoma spheroids.FEBS open bio · 2026Article
- The Expanding Role of Aquaporin-1, Aquaporin-3 and Aquaporin-5 as Transceptors: Involvement in Cancer Development and Potential Druggability.International journal of molecular sciences · 2025Review
- Evaluation of the Mammalian Aquaporin Inhibitors Auphen and Z433927330 in Treating Breast Cancer.Cancers · 2024Article
- Aquaporins in colorectal cancer: exploring their role in tumorigenesis, metastasis, and drug response.Human cell · 2024Review
- Peroxiporins in Triple-Negative Breast Cancer: Biomarker Potential and Therapeutic Perspectives.International journal of molecular sciences · 2024Review
- AQP3 and AQP5 Modulation in Response to Prolonged Oxidative Stress in Breast Cancer Cell Lines.Antioxidants (Basel, Switzerland) · 2024Article
- Expression patterns of aquaporins 1, 3, 5 in canine mammary gland carcinomas.The Journal of veterinary medical science · 2024Article
- The Involvement of Peroxiporins and Antioxidant Transcription Factors in Breast Cancer Therapy Resistance.Cancers · 2023Review
- Aquaglyceroporins in Human Breast Cancer.Cells · 2023Article
- Article
- Aquaporin-mediated dysregulation of cell migration in disease states.Cellular and molecular life sciences : CMLS · 2023Review
- Potential Galactagogue Effect of Tri-Than-Thip Remedy on Milk Synthesis in Lactating Rats: Impact on Milk Production-Related Parameters.International journal of medical sciences · 2023Article
- Aquaporins in Tumor.Advances in experimental medicine and biology · 2023Article
- Clinical value and molecular mechanism of AQGPs in different tumors.Medical oncology (Northwood, London, England) · 2022Review
- Comparisons of Forecasting for Survival Outcome for Head and Neck Squamous Cell Carcinoma by using Machine Learning Models based on Multi-omics.Current genomics · 2022Article
- Circular RNA Circ-STIL Contributes to Cell Growth and Metastasis in Hepatocellular Carcinoma via Regulating miR-345-5p/AQP3 Axis.Digestive diseases and sciences · 2022Article
- Aquaporin-5 in breast cancer.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is a common type of breast malignancy with high a propensity for metastasis and locoregional recurrence. The aim of the present study was to investigate the expression of aquaporin (AQP) 3 and AQP5, analyze their association with clinicopathological parameters and explore their clinical significance in tissue samples from patients with TNBC. Immunohistochemistry was performed to detect the expression patterns of AQP3 and AQP5 in 96 patients with TNBC who underwent surgery between 2007 and 2012. AQP3 and AQP5 were expressed primarily in the membrane and cytoplasm of tumor cells within TNBC tissues. AQP3 and AQP5 expression was notably stronger in carcinoma tissue compared with adjacent normal tissue. Overexpression of AQP3 and AQP5 was significantly associated with tumor size, lymph node status and local relapse/distant metastasis. In addition, aberrant overexpression of AQP5 was observed more frequently in TNBC tissues with higher Ki-67 expression than in those with lower Ki-67 expression. In univariate analysis, patients with TNBC with high AQP3 and AQP5 expression demonstrated poorer 5-year disease-free survival and overall survival compared with patients with low AQP3 and AQP5 expression. In multivariate analysis, the combined expression of AQP3 and AQP5 was an independent prognostic marker in patients with TNBC. The results of the present study suggest that the overexpression of AQP3 and AQP5 may serve as a novel therapeutic marker in patients with TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.